Combined PET/CT and Autoantibody Detection in Lung Nodules Diagnosis.

Objective: To assess the usefulness of combining positron emission tomography/computed tomography (PET/CT) with lung cancer autoantibody detection in identifying and managing lung nodules. Methods: The researchers identified 160 patients with pulmonary nodules admitted to their hospital between January 2018 and January 2021. These patients were designated as the experimental group. Additionally, 60 healthy individuals without pulmonary nodules were admitted to the hospital during the same period. The individuals constituted the control group. All study participants underwent digital PET/CT detection and had their lung cancer autoantibody levels determined through enzyme-linked immunosorbent assay. Further testing, such as puncture or surgical pathology, was performed for patients with lung nodules. The aim was to evaluate the significance of combining PET/CT with autoantibody detection in diagnosing and treating lung nodules. Results: The study found that testing multiple autoantibodies together increased sensitivity and accuracy compared to testing individual autoantibodies. Combining PET/CT screening with autoantibody detection improved the diagnostic rate for identifying lung nodules, including benign and suspected malignant ones. Several autoantibodies were significantly higher in the experimental group compared to the control group. Testing for multiple autoantibodies showed higher sensitivity and accuracy than testing for one. Pathological examination confirmed 129 benign nodules and 31 malignant nodules. The median SUVmax values were measured at 0.7 for benign nodules and 4.8 for malignant nodules. The diagnostic efficacy of PET/CT combined with autoantibodies was determined through comparison with pathology testing and was as follows: PET/CT combined with autoantibody detection > PET/CT > autoantibody detection. Conclusion: Combining PET/CT with the detection of autoantibodies enhances the positive diagnostic rate and accuracy of lung nodules in the case of lung cancer. The SUVmax also shows excellent potential as a supplement in diagnosing both benign and malignant lung nodules, providing valuable guidance in determining the pathological types.

Establishment of a prognosis prediction model for lung squamous cell carcinoma related to PET/CT: basing on immunogenic cell death-related lncRNA.

BACKGROUND: Immunogenic cell death (ICD) stimulates adaptive immunity and holds significant promise in cancer therapy. Nevertheless, the influence of ICD-associated long non-coding RNAs (lncRNAs) on the prognosis of patients with lung squamous cell carcinoma (LUSC) remains unexplored. METHODS: We employed data from the The Cancer Genome Atlas (TCGA)database to identify ICD-related lncRNAs associated with the prognosis of LUSC using univariate Cox regression analysis. Subsequently, we utilized the LOSS regression model to construct a predictive risk model for assessing the prognosis of LUSC patients based on ICD-related lncRNAs. Our study randomly allocated187 TCGA patients into a training group and 184 patients for testing the predictive model. Furthermore, we conducted quantitative polymerase chain reaction (qPCR) analysis on 43 tumor tissues from LUSC patients to evaluate lncRNA expression levelsPearson correlation analysis was utilized to analyze the correlation of risk scores with positron emission tomography/computed tomography (PET/CT) parameters among LUSC patients. RESULTS: The findings from the univariate Cox regression revealed 16 ICD-associated lncRNAs linked to LUSC prognosis, with 12 of these lncRNAs integrated into our risk model utilizing the LOSS regression. Survival analysis indicated a markedly higher overall survival time among patients in the low-risk group compared to those in the high-risk group. The area under the Receiver operating characteristic (ROC) curve to differentiate high-risk and low-risk patients was 0.688. Additionally, the overall survival rate was superior in the low-risk group compared to the high-risk group. Correlation analysis demonstrated a positive association between the risk score calculated based on the ICD-lncRNA risk model and the maximum standard uptake value (SUVmax) (r = 0.427, P = 0.0043) as well as metabolic volume (MTV)of PET-CT (r = 0.360, P = 0.0177) in 43 LUSC patients. CONCLUSION: We have successfully developed a risk model founded on ICD-related lncRNAs that proves effective in predicting the overall survival of LUSC patients.

Potential application of a green fiber laser in laser display systems.

This study explores the application of optical fiber lasers in display systems by integrating a P r3+-doped green all-fiber laser into a laser projection display system. As a control group to compare the results, a 520 nm semiconductor green laser diode module was integrated, similar to the experimental group. The color gamut and speckle performances were studied and compared. The results showed that the experimental group performed slightly better in the color gamut volume. The speckle contrast decreased rapidly in the experimental group when power increased. To our knowledge, this is the first study to apply a fiber laser to a laser display system. The results shed light on developing laser display systems with fewer or no speckle reduction elements.

All-fiber cyan laser at 491.5 nm.

We report, for the first time to our knowledge, a compact continuous-wave all-fiber cyan laser. The all-fiber cavity consists of a 443-nm fiber-pigtail laser diode as pump source, a 4.5-cm single-clad Pr3+-doped fluoride fiber, and two custom-built dielectric-coated fiber-pigtail mirrors in the visible spectral region. Downconversion cyan lasing at 491.5 nm is directly achieved, providing a maximum output power of 97.5 mW with a slope efficiency of 23.7% and a power fluctuation of less than 0.41%. Such a compact all-fiber cyan laser may be of great significance to expand the color reproduction range of laser displays, and has potential applications in fluorescence imaging, underwater communication, and detection.

Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features.

Objective: To evaluate the efficacy of the PD-1 inhibitor camrelizumab plus chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) and the prognostic differences of patients with different PET/CT features. Methods: Between December 2018 and October 2020, 100 patients with NSCLC assessed for eligibility treated in our institution were recruited and randomly assigned (1 : 1) to receive either the TC regimen chemotherapy (control group) or the TC regimen chemotherapy plus camrelizumab (study group). The primary endpoints were clinical efficacy, progression-free survival (PFS), and overall survival (OS). A decrease of max standard uptake value (SUVmax) of >30% in primary lung cancer was considered as metabolic remission. The prognostic differences of the eligible patients with different PET/CT features were assessed. Survival data were analyzed using the Kaplan-Meier method to obtain the survival rate and calculate the median survival time. Results: The metabolic remission rate and objective remission rate were significantly higher with chemotherapy plus camrelizumab versus chemotherapy alone. The study group had significantly higher CD3+ and CD4+ T-cell ratios and CD4+/CD8+ ratio and significantly lower CD8+ T-cell ratio than the control group after treatment. PFS (10 months versus 4 months) and OS (HR = 37.094, P ≤ 0.001) were better with camrelizumab plus chemotherapy versus stand-alone chemotherapy. The incidence of adverse events (AE) was similar between the two groups. The patients in the study group were stratified into metabolic remission and metabolic nonremission based on PET/CT results. Intersubgroup analysis showed significantly better PFS and OS in the metabolic remission group than in the nonmetabolic remission group. Conclusion: The camrelizumab plus chemotherapy as a first-line treatment option for NSCLC significantly increases the survival benefit. Metabolic status shown by PET/CT correlates with long-term prognosis and demonstrates a great potential for early assessment of efficacy to support the choice of treatment regimens.

Towards visible-wavelength passively mode-locked lasers in all-fibre format.

Mode-locked fibre lasers (MLFLs) are fundamental building blocks of many photonic systems used in industrial, scientific and biomedical applications. To date, 1-2 µm MLFLs have been well developed; however, passively mode-locked fibre lasers in the visible region (380-760 nm) have never been reported. Here, we address this challenge by demonstrating an all-fibre visible-wavelength passively mode-locked picosecond laser at 635 nm. The 635 nm mode-locked laser with an all-fibre figure-eight cavity uses a Pr/Yb codoped ZBLAN fibre as the visible gain medium and a nonlinear amplifying loop mirror as the mode-locking element. First, we theoretically predict and analyse the formation and evolution of 635 nm mode-locked pulses in the dissipative soliton resonance (DSR) regime by solving the Ginzburg-Landau equation. Then, we experimentally demonstrate the stable generation of 635 nm DSR mode-locked pulses with a pulse duration as short as ~96 ps, a radio-frequency signal-to-noise ratio of 67 dB and a narrow spectral bandwidth of <0.1 nm. The experimental results are in excellent agreement with our numerical simulations. In addition, we also observe 635 nm noise-like pulse operation with a wide (>1 nm) and modulated optical spectrum. This work represents an important step towards miniaturized ultrafast fibre lasers in the visible spectral region.

High-efficiency, yellow-light Dy3+-doped fiber laser with wavelength tuning from 568.7 to 581.9 nm.

We report, to the best of our knowledge, the first demonstration of a wavelength-tunable and highly efficient Dy3+-doped fiber laser operating in the yellow spectral region. A 2-m-long Dy3+:ZBLAN fiber pumped by a 447-nm GaN laser diode provides a strong down-conversion gain around 575 nm. A fiber end-facet mirror and a visible reflective grating in the Littrow configuration construct the resonant cavity and introduce the wavelength tunability. A stable yellow laser with a <0.05-nm narrow linewidth is achieved and continuously tuned from 568.7 nm to 581.9 nm, covering more than half of the yellow spectral range. The slope efficiency is as high as 34.9%, and the maximum output power is 142 mW at 576.44 nm, which is 13 times higher than previously reported. It is, to the best of our knowledge, the highest power and conversion efficiency of a yellow-light Dy3+-doped fiber laser with wavelength tunability.

Green/red pulsed vortex-beam oscillations in all-fiber lasers with visible-resonance gold nanorods.

Optical vortex beams are of tremendous interest in diverse applications for optical tweezers, high-resolution imaging, quantum information and optical communications. So far, these vortex laser sources largely rely on extra-cavity mode conversion by bulk optical elements (e.g. spatial light modulators, phase plates, etc.), resulting in a relatively poor purity, low conversion efficiency, non-compact structure and expensive package. Vortex beams generated directly from cavity-mode lasers is naturally an ideal solution, but almost all of them are not extended into the important visible spectral region. Here, we address the challenge through demonstrating, for the first time, visible-wavelength all-fiber pulsed vortex lasers. By using the fiber offset splicing technique and all-fiber visible resonators, 543.6 nm (green) and 634.7 nm (red) vortex beams are generated directly from Er3+: ZBLAN and Pr3+/Yb3+: ZBLAN fiber lasers with topological charges of ±1 and ±2, respectively. In particular, by exploiting an excellent visible-wavelength saturable absorber, visible-resonance-controlled gold nanorods, we further realize stable short-pulse operation of the 543.6 nm/634.7 nm vortex beams in the miniaturized visible fiber lasers. The green/red vortex laser pulses are ∼500 ns in duration, have a 40-400 kHz tunable repetition rate, and a >45 dB RF signal-to-noise ratio. This work may pave a path towards compact visible-wavelength pulsed vortex lasers for specific applications in STED microscopy and visible-light communications.

MiR-30a Decreases Multidrug Resistance (MDR) of Gastric Cancer Cells.

BACKGROUND The effectiveness of chemotherapy for gastric cancer is largely limited by either intrinsic or acquired drug resistance. In this study, we aimed to explore the association between miR-30a dysregulation and multidrug resistance (MDR) in gastric cancer cells. MATERIAL AND METHODS We recruited 20 patients with advanced gastric cancer. Chemosensitivity was assessed after completion of the chemotherapy. SGC-7901 and SGC-7901/DDP cells were transfected for miR-30a overexpression or knockdown. Then, MTT assay was performed to assess the IC50 of DPP and 5-FU in SGC-7901 and SGC-7901/DDP cells. Flow cytometry analysis was used to detect DPP- and 5-FU-induced cell apoptosis. Western blot analysis and immunofluorescence staining were used to assess EMT of the cells. RESULTS MiR-30a was significantly downregulated in the chemoresistant tissues. In both SGC-7901 and SGC-7901/DDP cells, miR-30a overexpression decreased the expression of P-gp, a MDR-related protein. MTT assay and flow cytometry analysis showed that miR-30a inhibition increased chemoresistance, while miR-30a overexpression decreased chemoresistance in gastric cancer cells. Both Western blot analysis and immunofluorescence staining confirmed that miR-30a inhibition decreased E-cadherin but increased N-cadherin in SGC-7901 cells, while miR-30a overexpression increased E-cadherin but decreased N-cadherin in SGC-7901 cells. CONCLUSIONS MiR-30a can decrease multidrug resistance (MDR) of gastric cancer cells. It is also an important miRNA modulating EMT of the cancer cells.